Literature DB >> 21833800

Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma.

Lola B Chambless1, Scott L Parker, Laila Hassam-Malani, Matthew J McGirt, Reid C Thompson.   

Abstract

Type 2 diabetes mellitus (DM) and obesity are known risk factors for poor outcomes in patients with systemic malignancies but are not well-studied in the brain tumor population. In this study we asked if type 2 DM and elevated body mass index (BMI) are independent risk factors for poor prognosis in patients with high-grade glioma (HGG.). We conducted a retrospective cohort study of 171 patients surgically treated for HGG at a single institution. BMI and records of pre-existing type 2 DM were obtained from medical histories. Variables associated with survival in a univariate analysis were included in the multivariate Cox model if P < 0.10. Variables with probability values >0.05 were then removed from the multivariate model in a step-wise fashion. Mean age at diagnosis was 55.0 ± 17.3 years. Fifteen (8.8%) patients had a history of type 2 DM. Fifty-eight (35.8%) patients had a BMI < 25, 55 (34.0%) BMI 25-30, and 49(30.2%) BMI > 30. Radiation therapy, temozolomide, and higher KPS score were independently associated with prolonged survival while increasing age was associated with decreased survival. DM (P = 0.001) and increasing BMI (P = 0.003) were found to be independently associated with decreased survival. Diabetics had a decreased median overall survival (312 vs. 470 days, P = 0.003) and PFS (106 vs. 166 days, P = 0.04) compared to non-diabetics. Increasing BMI (<25, 25-30, and >30) was also associated with decreased median PFS: 195 vs. 165 vs. 143 days, respectively. Pre-existing DM and elevated BMI are independent risk factors for poor outcome in patients with HGG.

Entities:  

Mesh:

Year:  2011        PMID: 21833800     DOI: 10.1007/s11060-011-0676-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

Review 1.  Metformin: its emerging role in oncology.

Authors:  Dragan Micic; Goran Cvijovic; Vladimir Trajkovic; Leonidas H Duntas; Snezana Polovina
Journal:  Hormones (Athens)       Date:  2011 Jan-Mar       Impact factor: 2.885

2.  Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression.

Authors:  A Perry; R B Jenkins; J R O'Fallon; P L Schaefer; D W Kimmel; M R Mahoney; B W Scheithauer; S M Smith; E M Hill; T J Sebo; R Levitt; J Krook; L K Tschetter; R F Morton; J C Buckner
Journal:  Cancer       Date:  1999-08-15       Impact factor: 6.860

3.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis.

Authors:  Susanna C Larsson; Nicola Orsini; Alicja Wolk
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

Review 4.  Metformin and cancer: new applications for an old drug.

Authors:  Taxiarchis V Kourelis; Robert D Siegel
Journal:  Med Oncol       Date:  2011-02-08       Impact factor: 3.064

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.

Authors:  E Pozsgai; A V Schally; G Halmos; F Rick; S Bellyei
Journal:  Horm Metab Res       Date:  2010-07-27       Impact factor: 2.936

7.  Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank Attenello; Khoi Than; Amado Jimenez Ruiz; Alessandro Olivi; Alfredo Quiñones-Hinojosa
Journal:  Neurosurgery       Date:  2008-08       Impact factor: 4.654

8.  Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma.

Authors:  Rachel L Derr; Xiaobu Ye; Melissa U Islas; Serena Desideri; Christopher D Saudek; Stuart A Grossman
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

Review 9.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Authors:  Hashem B El-Serag; Howard Hampel; Fariba Javadi
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

10.  Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains.

Authors:  R Lammers; A Gray; J Schlessinger; A Ullrich
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

View more
  30 in total

1.  Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas.

Authors:  Zhen-Qiang He; Chao Ke; Fuad Al-Nahari; Hao Duan; Cheng-Cheng Guo; Yang Wang; Xiang-Heng Zhang; Yin-Sheng Chen; Zhi-Gang Liu; Jian Wang; Zhong-Ping Chen; Xiao-Bing Jiang; Yong-Gao Mou
Journal:  J Neurooncol       Date:  2017-01-11       Impact factor: 4.130

2.  Prognostic Significance of Hyperglycemia in Patients with Brain Tumors: a Meta-Analysis.

Authors:  Hongwei Liu; Zhixiong Liu; Bing Jiang; Xiping Ding; Lei Huo; Xin Wan; Jinfang Liu; Zhenyun Xia
Journal:  Mol Neurobiol       Date:  2015-02-17       Impact factor: 5.590

Review 3.  Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma.

Authors:  Angela Poff; Andrew P Koutnik; Kathleen M Egan; Solmaz Sahebjam; Dominic D'Agostino; Nagi B Kumar
Journal:  Semin Cancer Biol       Date:  2017-12-30       Impact factor: 15.707

4.  Underweight and weight loss are predictors of poor outcome in patients with brain metastasis.

Authors:  Anna Lareida; Robert Terziev; Bettina Grossenbacher; Nicolaus Andratschke; Patrick Roth; Sabine Rohrmann; Rolf Stahel; Matthias Guckenberger; Emilie Le Rhun; Michael Weller; Fabian Wolpert
Journal:  J Neurooncol       Date:  2019-09-30       Impact factor: 4.130

5.  Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation.

Authors:  Yuanying Gong; Yufang Ma; Maksim Sinyuk; Sudan Loganathan; Reid C Thompson; Jann N Sarkaria; Wenbiao Chen; Justin D Lathia; Bret C Mobley; Stephen W Clark; Jialiang Wang
Journal:  Neuro Oncol       Date:  2015-07-01       Impact factor: 12.300

6.  Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification.

Authors:  G Ening; F Osterheld; D Capper; K Schmieder; C Brenke
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-11       Impact factor: 4.553

7.  Prediagnostic body weight and survival in high grade glioma.

Authors:  Erin M Siegel; L Burton Nabors; Reid C Thompson; Jeffrey J Olson; James E Browning; Melissa H Madden; Gang Han; Kathleen M Egan
Journal:  J Neurooncol       Date:  2013-05-11       Impact factor: 4.130

Review 8.  Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review.

Authors:  Sarah Travers; N Scott Litofsky
Journal:  Brain Sci       Date:  2021-04-23

9.  Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

Authors:  Niamh Coleman; Vasiliki Michalarea; Scheryll Alken; Karim Rihawi; Raquel Perez Lopez; Nina Tunariu; Ann Petruckevitch; L R Molife; Udai Banerji; Johann S De Bono; Liam Welsh; Frank Saran; Juanita Lopez
Journal:  J Neurooncol       Date:  2018-04-10       Impact factor: 4.130

10.  Association of metabolic syndrome with glioblastoma: a retrospective cohort study and review.

Authors:  Lisa R Rogers; Quinn T Ostrom; Julia Schroer; Jaime Vengoechea; Li Li; Stanton Gerson; Charles J Nock; Mitchell Machtay; Warren Selman; Simon Lo; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  Neurooncol Pract       Date:  2020-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.